Scholarlink

Purpose <p>To evaluate the impact of detrusor muscle (DM) absence on oncological outcomes in patients with pTaHG within a large, multicenter cohort.</p> Methods <p>This is a retrospective multicenter study based on a national database including 12 international expert centers. All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival.</p> Results <p>Overall, 418 patients had either pTaHG with DM (<i>n</i> = 365;87.3%) or without DM (<i>n</i> = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; <i>p</i> = 0.2) and the 5-year PFS (75% vs. 86%; <i>p</i> = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41–1.15]; <i>p</i> = 0.15) and PFS (HR = 0.68; 95%CI= [0.27–1.69]; <i>p</i> = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (<i>p</i> = 0.1) and 5-year PFS (<i>p</i> = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09–0.93]; <i>p</i> = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; <i>p</i> = 0.04).</p> Conclusion <p>Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial carcinoma of the bladder? The end of the “jump” of the lamina propria layer myth

  • 期刊论文

  • 发表日期：

    2025年5月26日

查看全文
  • Gabrielle Tissot,
  • Pierre-Etienne Gabriel,
  • Ulysse Dubuet,
  • Sophie Régnier,
  • Idir Ouzaid,
  • Marco Moschini,
  • Francesco Soria,
  • David D’Andrea,
  • Shahrokh F. Shariat,
  • Alexandra Budowski,
  • Cédric Poyet,
  • Mathieu Roumiguie,
  • Mario Alvarez Maestro,
  • Alberto Briganti,
  • Wojciech Krajewski,
  • Kees Hendricksen,
  • Hans Veerman,
  • Luca Afferi,
  • Agostino Mattei,
  • Carlo Di Bona,
  • Stefania Zamboni,
  • Claudio Simeone,
  • Ronan Thenault,
  • Gregory Verhoest,
  • Jean-François Hermieu,
  • Evanguelos Xylinas

摘要

Purpose

To evaluate the impact of detrusor muscle (DM) absence on oncological outcomes in patients with pTaHG within a large, multicenter cohort.

Methods

This is a retrospective multicenter study based on a national database including 12 international expert centers. All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival.

Results

Overall, 418 patients had either pTaHG with DM (n = 365;87.3%) or without DM (n = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; p = 0.2) and the 5-year PFS (75% vs. 86%; p = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41–1.15]; p = 0.15) and PFS (HR = 0.68; 95%CI= [0.27–1.69]; p = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (p = 0.1) and 5-year PFS (p = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09–0.93]; p = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; p = 0.04).

Conclusion

Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients.